Thrombolytic Therapies for Ischemic Stroke Management

Ischaemic stroke, a leading cause of disability and mortality worldwide, arises from the occlusion of cerebral arteries by blood clots. Restoring perfusion rapidly is paramount to salvage penumbral tissue and improve clinical outcomes. Pharmacological thrombolysis with tissue plasminogen activator (tPA) remains the standard of care, but is constrained by a narrow therapeutic window, risk of intracranial haemorrhage and incomplete recanalisation. Recent advances seek to enhance clot dissolution efficacy while mitigating bleeding complications. Strategies include targeted delivery of thrombolytic agents via nanocarriers, synergistic use of ultrasound or light to improve thrombus penetration, and development of nonpharmaceutical modalities that combine mechanical disruption with biochemical actions. These innovations aim to extend the treatment window, reduce systemic exposure, and enable image-guided personalised interventions. Integration of molecular imaging and responsive materials promises timely assessment of clot burden and dynamic adjustment of therapy. Collectively, emerging thrombolytic platforms are reshaping the management of ischaemic stroke by uniting precision delivery, multimodal action and real-time monitoring to improve safety and efficacy on a global scale.

Research from Nature Portfolio

Researchers have engineered a self-propelled nano-penetrator co-assembled from a photothermal dye and a nitric oxide donor. Under near-infrared irradiation, this construct generates heat and NO, drives autonomous clot homing and deep penetration, and achieves combined photothermal-mechanical thrombolysis without the bleeding risk associated with conventional drugs. In animal models of arterial and venous thrombosis and acute ischaemic stroke, the nano-penetrator showed superior clot clearance and prevented recurrence. This work exemplifies a nonpharmaceutical, image-guided approach that integrates self-navigation, multimodal action and recurrence prevention within a single platform.

Thrombolytic Therapies for Ischemic Stroke Management publication trend

The graph below shows the total number of articles in thrombolytic therapies for ischemic stroke management across all publications each year (not limited to Nature Index journals).

Technical terms

Tissue plasminogen activator (tPA): An enzyme that converts plasminogen to plasmin, initiating fibrin degradation and clot lysis.

Photothermal therapy: Use of light-absorbing agents to convert light energy into heat for targeted disruption of biological structures, such as thrombi.

Metal–organic framework (MOF): A porous, crystalline material composed of metal ions and organic ligands, used here as a nanoenzyme for catalysis and gas generation.

Ultrasound cavitation: Formation and collapse of gas-filled bubbles under ultrasonic waves to mechanically disrupt clots and enhance drug delivery.

Reactive oxygen species (ROS): Highly reactive molecules derived from oxygen that can damage cells but may also be scavenged to reduce inflammation after thrombolysis.

References

1. Molecularly self‐fueled nano-penetrator for nonpharmaceutical treatment of thrombosis and ischemic stroke. Nature Communications (2023).
2. Ultrasound Trigger Ce‐Based MOF Nanoenzyme For Efficient Thrombolytic Therapy. Advanced Science (2024).
3. P-Selectin mediates targeting of a self-assembling phototherapeutic nanovehicle enclosing dipyridamole for managing thromboses. Journal of Nanobiotechnology (2023).